| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 1.055 | 1.250 | 892 | 836 | 809 | 796 | 775 | 789 | 792 | 798 |
| Gross Profit/Loss - EUR | -1.055 | -1.250 | -892 | -836 | -809 | -796 | -775 | -789 | -792 | -798 |
| Net Profit/Loss - EUR | -1.055 | -1.250 | -892 | -836 | -809 | -796 | -775 | -789 | -792 | -798 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nanotehnologii Medicale Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 862 | 541 | 780 | 800 | 931 | 1.045 | 1.163 | 1.308 | 1.462 | 1.577 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 682 | 516 | 657 | 792 | 921 | 1.045 | 1.160 | 1.302 | 1.436 | 1.566 |
| Cash | 179 | 25 | 123 | 8 | 10 | 0 | 3 | 6 | 25 | 11 |
| Shareholders Funds | -2.248 | -3.475 | -4.308 | -5.065 | -5.776 | -6.463 | -7.094 | -7.905 | -8.673 | -9.423 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 3.110 | 4.016 | 5.088 | 5.865 | 6.706 | 7.508 | 8.257 | 9.213 | 10.135 | 11.000 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7219 - 7219" | |||||||||
| CAEN Financial Year |
7219
|
|||||||||
Comments - Nanotehnologii Medicale Srl